Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

April 30, 2009

Study Completion Date

November 30, 2009

Conditions
Carcinoma, Small Cell
Interventions
DRUG

Topotecan

Topotecan 4mg/m2 IV on days 1, 8.

DRUG

carboplatin

Carboplatin AUC=5 IV day 1 only .

Trial Locations (16)

29303

Spartanburg Regional Medical Center, Spartanburg

30501

Northeast Georgia Medical Center, Gainesville

33805

Watson Clinic Center for Cancer Care and Research, Lakeland

33901

Florida Cancer Specialists, Fort Myers

36207

Northeast Alabama Regional Medical Center, Anniston

37023

Tennessee Oncology, PLLC, Nashville

37404

Associates in Hematology Oncology, Chattanooga

38017

Family Cancer Center, Collierville

40207

Consultants in Blood Disorders and Cancer, Louisville

42101

Graves-Gilbert Clinic, Bowling Green

45242

Oncology Hematology Care, Cincinnati

49503

Grand Rapids Clinical Oncology Program, Grand Rapids

59802

Montana Cancer Institute Foundation, Missoula

71301

Hematology Oncology Life Center, Alexandria

72401

Northeast Arkansas Clinic, Jonesboro

04101

Mercy Hospital, Portland

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER